(Q33825948)

29 July 2017

1 reference

title

Herpes zoster: focus on treatment in older adults (English)

1 reference

29 July 2017

1 reference

Whitley RJ

1

1 reference

29 July 2017

Gnann JW

series ordinal

2

1 reference

29 July 2017

publication date

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

44

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

145-154

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

29 July 2017

1 reference

7 January 2021

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

The epidemiology of varicella and its complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Oral acyclovir in the treatment of acute herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Recent advances in varicella-zoster virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Pharmacokinetics of acyclovir after intravenous and oral administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

The incidence of herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Assessment of pain in herpes zoster: lessons learned from antiviral trials

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Pain and its persistence in herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Oral acyclovir in herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Postherpetic neuralgia--pathogenesis, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Acyclovir. Pharmacology and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Comparative biology of latent varicella-zoster virus and herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Population-based study of herpes zoster and its sequelae

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

The identification of risk factors associated with persistent pain following herpes zoster.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Herpes zoster: risk categories for persistent pain

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900064-9

7 January 2021

10.1016/S0166-3542(99)00064-9

Identifiers

DOI

1 reference

29 July 2017

1 reference